The EPS projection of Aduro BioTech Inc (NASDAQ:ADRO) for quarter ended 2016-09-30 is $-0.47. A week before, the EPS forecast was $-0.47 against target of $-0.47, a month earlier. This estimate stood at $-0.47 60 days earlier versus forecast of $-0.47 90 days earlier, confirming a deviation of 0%.
Aduro BioTech Inc (NASDAQ:ADRO) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 2, 0 and 2, respectively.
The downgrade of EPS estimates for Aduro BioTech Inc (NASDAQ:ADRO) in the preceding 120, 60, 30 and 90 days were 1, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Aduro BioTech Inc (NASDAQ:ADRO) was $-0.47. This projection was computed after accounting 4 calls. As reported on 2016-05-02 the EPS was $-0.45. The change was $-0.15, demonstrating a percentage deviation of -50%. The projections confirmed a standard deviation of 0.18.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Aduro BioTech Inc (NASDAQ:ADRO) stands at $4.478 and the median estimate at $3.902. Almost 4 analysts announced their estimates.
The highest estimate is $6.41 while the lowest target is $3.7 showing standard deviation of 1.301%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. Aduro BioTech Inc (NASDAQ:ADRO) stated that the change in forecast was -43.143%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...